Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMINI 1: tolebrutinib versus teriflunomide in relapsing multiple sclerosis
jRCT2021200035Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of tolebrutinib in multiple sclerosis (MS) (2 arms), sponsored by Sanofi. Primary endpoint: Annualized adjudicated relapse rate. Started Feb 2021; status: completed.
02
Drugs
tolebrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on jRCT2021200035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021200035.